← ANALYST RATINGS · TIPRANKS
Corcept Therapeutics (CORT): analyst forecast and price target
Analyst consensus
Moderate Buy4 Buy0 Hold1 Sell
Ratings of 5 analysts in the last 3 months12-month forecast
Based on 5 price targets given in the last 3 months, the average target is $141, the highest $165, the lowest $50.00. The average is +28.0% from the last price of $110.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Edward Nash★★★★★★★★★★#204 · hits 52% · avg +29.5% | Canaccord Genuity | $161 | Buy | +46.2% | Reiterated | 14.10.26on TipRanks Oct 15 07:30 | −0.3%next day −2.7% | ↗ |
| David Amsellem★★★★★★★★★★#347 · hits 62% · avg +15.7% | Piper Sandler | $165 | Buy | +49.8% | Reiterated | 07.10.26on TipRanks 07:25 | +0.3%next day −0.5% · 5 days −1.8% | ↗ |
| Swayampakula Ramakanth★★★★★★★★★★#445 · hits 47% · avg +21.2% | H.C. Wainwright | $165 | Buy | +49.8% | Reiterated | 01.10.26on TipRanks 10:35 | −1.2%next day +1.2% · 5 days +2.7% | ↗ |
| AI xAi Medical - PharmaceuticalsxAI Grok-3 | TipRanks - xAI | $128 → $131+2.3% | Buy | +18.9% | Reiterated | 23.09.26on TipRanks 19:05 | — | |
| AI DeepSeek Medical - PharmaceuticalsDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $124 → $127+2.4% | Hold | +15.3% | Reiterated | 23.09.26on TipRanks 19:05 | — | |
| AI OpenAI Medical - PharmaceuticalsOpenAI 5.2 | TipRanks - OpenAI | $130 → $134+3.1% | Buy | +21.6% | Reiterated | 23.09.26on TipRanks 19:05 | — | |
| AI Anthropic Medical - PharmaceuticalsAnthropic Opus-4.6 | TipRanks - Anthropic | $121 → $129+6.6% | Buy | +17.1% | Upgrade | 23.09.26on TipRanks 19:05 | — | |
| AI Google Medical - PharmaceuticalsGemini 3-pro | TipRanks - Google | $128 → $135+5.5% | Buy | +22.5% | Reiterated | 23.09.26on TipRanks 19:05 | — | |
| AI PerPlexity Medical - PharmaceuticalsPerPlexity SonarPro | TipRanks - PerPlexity | $132 → $131−0.8% | Buy | +18.9% | Reiterated | 23.09.26on TipRanks 19:05 | — | |
| Srikripa Devarakonda★★★★★★★★★★#200 · hits 62% · avg +26.3% | Truist Financial | $50.00 → $164+228.0% | Buy | +48.9% | Initiated | 18.08.26on TipRanks 07:25 | +1.5%next day +0.6% · 5 days +4.8% | ↗ |
| Kalpit Patel★★★★★★★★★★#1436 · hits 39% · avg +16.1% | Wolfe Research | $50.00 | Sell | −54.6% | Reiterated | 29.07.26on TipRanks Jul 30 11:25 | +0.2%next day +25.6% · 5 days +13.6% | ↗ |
| Ashwani Verma★★★★★★★★★★#1305 · hits 60% · avg +13.4% | UBS | $72.00 | Buy | −34.6% | Upgrade | 13.05.26on TipRanks 05:40 | +11.0%next day +1.3% · 5 days +3.6% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Corcept Therapeutics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $141 at a price of $115 (+22.4%); now: $141 at $110 (+28.0%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 11 | 5 | 3 | 0 | 0 | 0 |
| Buy | 5 | 5 | 10 | 10 | 9 | 7 |
| Hold | 1 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 2 | 2 | 2 | 0 |
Earnings and sales forecast
Next report: 04.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $0.79 (from $0.61 to $1.03). Last quarter: $0.36.
Sales
Next quarter’s sales estimate — $324M (from $274M to $350M). Last quarter: $256M.
Best top-analyst consensus in the sector · Healthcare
About Corcept Therapeutics
- CEO: Joseph K. Belanoff
- Employees: 730
- 101 Redwood Shores Parkway, Redwood City, CA, 94065, US
- www.corcept.com
Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable. The company's development pipeline is robust, featuring relacorilant, which is being advanced for Cushing's syndrome. It is also investigating a combination of relacorilant with nab-paclitaxel; this pairing has concluded Phase II clinical trials for advanced ovarian tumors and is additionally being studied for conditions involving cortisol excess. Furthermore, Corcept is developing distinct selective cortisol modulators for specific indications such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain, alongside research into FKBP5 gene expression assays.
Data from the stock’s TipRanks forecast page, read 128 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗